My Google Profile+ Jill Heidi Osborne is the president and founder of the
Interstitial Cystitis Network, a health education company dedicated to interstitial cystitis, bladder pain syndrome and other pelvic pain disorders.
As the editor and lead author of the ICN and the
IC Optimist magazine, Jill is proud of the academic recognition that her website has achieved. The University of London rated the ICN as the top IC website for accuracy, credibility, readability and quality.
(Int Urogynecol J - April 2013). Harvard Medical School rated both Medscape and the ICN as the top two websites dedicated to IC.
(Urology - Sept 11). For many years, Jill served on the
Congressionally Directed Medical Research Panel (US Army) where she collaborated with researchers to evaluate new IC research studies for possible funding. Jill has conducted and/or collaborates on a variety of IC research studies on new therapeutics, pain care, sexuality, the use of medical marijuana, menopause and the cost of treatments, shining a light on issues that influence patient quality of life.
An IC support group leader and national spokesperson for the past 20 years, she has represented the IC community on radio, TV shows, at medical conferences. She has written hundreds of articles on IC and its related conditions.
Jill has a Bachelors Degree in Pharmacology and a Masters in Psychology, Jill was named Presidential Management Intern (aka Fellowship) while in graduate school. (She was unable to earn her PhD due to the onset of her IC.) She spends the majority of her time providing
WELLNESS COACHING for patients in need and developing new, internet based educational and support tools for IC patients, including new live IC Support Group Meetings via Youtube and the
“Living with IC” video series. Jill was diagnosed with IC at the age of 32 but first showed symptoms at the age of 12.
(January 2015) The only oral medication FDA approved for interstitial cystitis in the USA, Elmiron® (aka pentosan polysulfate), has received mixed results in research studies. But, for the patient community, the dominant issue is the cost as prices have increased steadily in the last few years. We’re interested in hearing from you, the IC patient, about your experience with Elmiron®. 